Advanced Malignant Mesothelioma
14
0
0
10
Key Insights
Highlights
Success Rate
91% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
7.1%
1 terminated out of 14 trials
90.9%
+4.4% vs benchmark
0%
0 trials in Phase 3/4
50%
5 of 10 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 10 completed trials
Clinical Trials (14)
HMPL-453 in Advanced Malignant Mesothelioma
Quality of Life and Survivorship Care in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
Cryotherapy in Treating Patients With Lung Cancer That Has Spread to the Other Lung or Parts of the Body
PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By Surgery
S0509 - AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By Surgery
Pazopanib in Treating Patients With Malignant Pleural Mesothelioma
Cediranib Maleate in Treating Patients With Malignant Mesothelioma That Cannot Be Removed By Surgery
Sunitinib in Treating Patients With Advanced Malignant Pleural Mesothelioma
Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Malignant Mesothelioma
AMG 102, Pemetrexed Disodium, and Cisplatin in Treating Patients With Malignant Pleural Mesothelioma
Erlotinib in Treating Patients With Malignant Mesothelioma of the Lung
Gefitinib in Treating Patients With Malignant Mesothelioma
EF5 in Detecting Oxygen Level and Blood Vessels in Tumor Cells of Patients Undergoing Photodynamic Therapy for Intraperitoneal or Pleural Cancer
Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction